All In Biotech

Drug Trial Radar · NCT03574402

Phase II Umbrella Study Directed by Next Generation Sequencing

An Open-label, Multi-center, Phase II Umbrella Study to Assess Efficacy of Targeted Therapy or Immunotherapy Directed by Next Generation Sequencing (NGS) in Chinese Patients With Advanced NSCLC (TRUMP)

Last checked: Nov 20, 2026Latest source record: Dec 6, 2022 (this record)Source: ClinicalTrials.govMethods & limitations

Status unknown

Status

Status unknown

Enrollment

400

Planned (sponsor's estimate)

Start

Jul 9, 2018

Primary completion

Dec 30, 2022

Study completion Dec 30, 2024

Sponsor

Lead sponsor
Guangdong Association of Clinical TrialsAcademic, hospital or other
Sponsor type
Academic, hospital or other
Collaborators
Chinese Thoracic Oncology Group
First posted
Jul 2, 2018

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Non randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This phase II, umbrella trial study directed by next generation sequencing (NGS) works in Chinese patients with advanced stage NSCLC who never received any anti-tumor treatment. The purpose of this study is to evaluate efficacy of targeted therapies or immunotherapy to NSCLC patients whose tumor harbors a genomic variant known to be a drug target or to predict sensitivity to a drug.

Conditions

  • Carcinoma, Non-Small-Cell Lung

Interventions

  • Avitinib MaleateDrug

    300mg orally (PO) twice daily (BID) on day 1-28.

  • AfatinibDrug

    40mg orally once a day, 28 days as one cycle.

  • CrizotinibDrug

    250mg PO QD on days 1-28. 28 days as one cycle.

  • X-396Drug

    225mg PO QD on days 1-28. 28 days as one cycle.

  • ChidamideDrug

    30mg orally twice weekly, 28 days as one cycle.

  • Pyrotinib MaleateDrug

    400mg PO QD on days 1-28. 28 days as one cycle.

  • AZD3759Drug

    200mg PO BID on days 1-28. 28 days as one cycle.

  • PirotinibDrug

    60mg PO QD/40mg PO BID on days 1-28. 28 days as one cycle.

  • NimotuzumabDrug

    400mg, iv gtt. on day 1,8,15. 21 days as one cycle.

  • PemetrexedDrug

    500mg/m\^2, iv gtt. Q3W. 21 days as one cycle.

  • CisplatinDrug

    75mg/m\^2, iv gtt. Q3W on day1. 21 days as one cycle.

  • SintilimabDrug

    200mg iv gtt. Q3W on day1. 21 days as one cycle.

  • GemcitabineDrug

    1g/m\^2 iv gtt. on day1,8. 21 days as one cycle.

  • GemcitabineDrug

    1.25g/m\^2 iv gtt. on day1,8. 21 days as one cycle.

  • CarboplatinDrug

    AUC5 iv gtt. Q3W on day1. 21 days as one cycle.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Response rate (RR)Time frame: 24 months

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Guangdong Lung Cancer Institute, Guangdong Provincial People's Hospital, Guangdong Academy of Medical Sciences, School of Medicine, South China University of Technology

    Guangzhou, Guangdong, China · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.